Tulisokibart, an anti-TL1A monoclonal antibody, demonstrates endoscopic and clinical efficacy in phase 2 trials for both Crohn’s disease and ulcerative colitis refractory to standard therapies.
In Crohn’s disease, 26% achieved endoscopic response at week 12; in ulcerative colitis, clinical remission was significantly higher with tulisokibart versus placebo (26% vs. 1%).
Safety profile was favorable, with most adverse events mild to moderate and no deaths reported.
Ongoing phase 3 trials will further assess long-term efficacy and safety.
Clinical Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.